Although research into potential novel approaches to treatment in triple-negative breast cancer does not seem to raise any ambiguity due to its dismal prognosis [4], this cannot be said for ER-positive, PR positive, and HER2-negative breast cancer because these patients show a rather favorable outcome [23]. The gene discussed is ESR1; the disease is breast carcinoma.